

Recent developments on Novel Heterocyclic compounds Thiadiazoles and Heterocyclic compounds for Covid 19 Targets in Drug Discovery

Abstract





This article mainly reviews the recent developments in the synthesis of novel 1,3,4-Thiadiazoles and also recent development of drug molecules for the treatment of Covid 19. The Thiadiazole heterocycle and its derivatives are the most important class of compounds among various heterocyclic compounds due to their wide range of biological activities and pharmaceutical importance. Thiadiazole moiety exists as a principal structural pharmacophore in the combination of drug categories such as antimicrobial, anti-inflammatory, analgesic, antiepileptic, antiviral, antineoplastic, antitubercular agents. In this review article, we have attempted to show various synthetic procedures of thiadiazole derivatives along with their pharmacological activities and also the recent studies on Antiviral targets for the discovery of new drugs to combat Covid19 like viruses.

Key word: Heterocyclic compounds, cyclic compounds, Drug Discovery, Covid 19

Introduction


Heterocyclic compounds are the cyclic compounds possessing one or more atom(s) of other elements along with the carbon atoms in the ring system. Nitrogen, sulfur, oxygen are some of the most commonly used heteroatoms.

Thiadiazole is a five-membered cyclic system possessing hydrogen bonding domain, the sulfur atom, and nitrogen atoms. There are four types of thiadiazoles: 1,2,5-, 1,2,4-, 1,2,3- and 1,3,4-thiadiazole. 1,3,4-thiadiazoles have become a versatile class of heterocycles and a great area for academicians and researchers due to their wide range of biological activity.




1,2,5-thiadiazole 1,2,4-thiadiazole 1,2,3-thiadiazole 1,3,4-thiadiazole


A number of thiadiazole-containing drugs are reported in the literature and marketed as shown below.




acetazolamide



methazolamide



Sulfamethizole




Megazol


1,3,4-Thiadiazole and its reactivity

Several researchers have used different synthetic strategies to obtain the desired target thiadiazole. Some of the synthetic methodologies are reviewed in this article and shown below.


The ring nitrogens react with electrophiles to afford either 1,3,4-thiadiazolium salts or 1,3,4-thiadiazol-2(3H)-ones depending on the tautomeric stability of the substituents at the C-2 or C-5 positions. 2-Amino-1,3,4-thiadiazole reacts with chloroacetone to furnish the N-alkylated thiadiazolimine. Reaction with 1-chloro-propan-2-one to provide the N-alkylated thiadiazolimine and reaction with trimethylsilyl methyl trifluoromethane sulfonate to give 1,3,4-thiadiazolium salts respectively.




Due to the low electron density at the carbon atoms in 1,3,4-thiadiazole such reactions as nitration, sulphonation, acetylation, halogenations normally do not take place. C-Acylation can be accomplished via rearrangement of intermediate N-acylthiadiazolium salts while radical halogenation can give chlorinated or brominated 2-halo-5-substituted thiadiazoles. 2-aminosubstituted 1,3,4-thiadiazole derivatives react with bromine and acetic acid to give the 5-bromo derivatives.




Halo-substituted thiadiazoles are highly activated and react with a variety of nucleophiles. Carbon-based nucleophiles such as malonate have been used in the synthesis of 2-substituted thiadiazoles. When 2-chlorothiadiazole was treated with ethyl acetate in the presence of sodium hexamethyldisilazane (NaHMDS), the 5-phenyl-1,3,4-thiadiazol-2-yl acetic ester was obtained as shown in the following reaction.




Reaction of various alkylating agents with unsubstituted and 5-substituted thiadiazoles yield 3-alkyl-1,3,4-thiadiazolium salts. These salts were deprotonated with ethoxide to produce carbenes which were then trapped with aromatic isocyanate to yield spirocyclic compounds as mentioned below.




According to Azaam M M et al., (2018), an α -aminophosphonate containing thiadiazole was synthesized by reacting 2-amino-5-methyl-1,3,4-thiadiazole with various aldehydes, triphenyl phosphite and mixed valence Cu(I)/Cu(II) inorganic coordination polymer as a catalyst. The products were characterized and their anticancer activity was carried out on human hepatocellular carcinoma and breast adenocarcinoma cell lines using MTT assay method. These compounds were found to show good anticancer activity.




In another report, Abdelhamid A O et al., (2016) synthesized some 1,3,4-thiadiazole derivatives by the reaction of hydrazonoyl halides with 3-(1H-indol-2-yl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide, hydrazonoyl halides with N'-(1-(1H-indol-3-yl)ethylidene)-2-cyanoacetohydrazide to form 1,3,4-thiadiazole derivatives. The compounds have been characterized and screened for their antitumor activity against the MCF-7 human breast carcinoma cell line. These compounds are novel and found to show good activity.




In another approach, Amir M et al., in 2017 synthesized 6-substituted-1, 2, 4-triazolo [3, 4-b]-1, 3, 4-thiadiazole from naphthoxy acetic acid. The products were characterized and screened for anti-inflammatory activity. These compounds were reported to be showing promising activity.



Patel H M, Noolvi M N, Sethi N S, Gadad A K, Cameotra S S et al., in 2017 synthesized imidazo [2, 1-b][1, 3, 4] thiadiazole derivatives and evaluated for their antitubercular activity.




Quinazolin-4 (3H)-one derivatives containing a 1, 2, 4-triazolo [3, 4-b][1, 3, 4] thiadiazole moiety were synthesized by Lv X, Yang L, Fan Z, Bao X et al., in 2017, characterized by the spectral data and evaluated their antimicrobial activities.




R₁ = Phenyl, Methoxy


New 1-thia-4-azaspiro [4.5] decane, derived from thiazolopyrimidine and 1, 3, 4-thiadiazolethioglycosides were synthesized by Fiefel E M et al., in 2017 and evaluated their anticancer activity. These compounds were found to show interesting activity.




In another approach, Ameen H A, Qasir A J et al., in 2017 have synthesized 2-amino-5-mercapto-1,3,4-thiadiazole derivatives and evaluated them for the antimicrobial activity as shown in the following scheme.




Kumari R, Sharma B B, Dubey V et al., in 2017 synthesized 1,3,4-thiadiazole derivatives and evaluated for their anti-inflammatory activities.



Kothawade P, Bhalerao R, Kulkarni G et al., in 2017 synthesized the following 1, 3, 4- thiadiazole derivatives and evaluated for its antidiabetic and antioxidant activity. The aryl carboxylic acid is treated with thiosemicarbazide in ethanol in the presence of catalytic quantity of sulfuric acid to obtain the respective thiadiazole.




Previously in a slightly different approach, Abdo N Y, Kamel M M. et al., in 2015 synthesized 1, 3, 4- thiadiazole derivatives and evaluated for its anticancer activity.




R = Toluene, Anisole

Madhavi, B. and Veera Raghava Sharma, G. have been focusing on the synthesis of novel thiazolidinoneanalogs as shown in the following scheme for their biological activity studies including their role in treating viral diseases such as Covid 19 and similar viruses.




Antibacterial and antifungal activity

Aggarwal et al synthesized novel nalidixic acid-based 1,3,4-thiadiazoles and demonstrated their antimicrobial activity. The bacterial stain used included gram-positive bacteria, *Staphylococcus aureus* and *Bacillus subtilis*, and Gram-negative bacteria, namely *Escherichia coli*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*. Compound with 1,4-bis(methylene)benzene group as a spacer between two 1,3,4-thiadiazoles showed remarkable antibacterial activity (MIC, 31.25–125 $\mu\text{g}/\text{mL}$) against all the tested organisms.




R- $-(\text{CH}_2)_0$; $-(\text{CH}_2)_4$; $-(\text{CH}_2)_6$; $-(\text{CH}_2)_8$; $-\text{CH}_2\text{C}_6\text{H}_4\text{CH}_2-$


Teja et al synthesized some novel thiazolidino[2,3]imidazo[4,5-b]quinoxaline derivatives and evaluated their antimicrobial activity against gram positive (*S. aureus* and *Bacillus cereus*) and Gram-negative bacteria (*Escherichia coli* and *Pseudomonas aeruginosa*) by paper disc diffusion method. The minimum inhibitory concentrations (MIC) of the compounds were also determined by using the agar streak dilution method. Ciprofloxacin was used as reference drug. Many compounds showed good antimicrobial activities




Farshori et al synthesized a novel series of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-thiadiazoles and screened for their antimicrobial activity against *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Streptococcus pyogenes* and *Klebsiella pneumoniae* bacterial strains by disc diffusion method. Minimum inhibitory concentrations (MICs) were determined by broth dilution techniques which were in range of 6.25-12.5 µg/ml by using Chloramphenicol and Griseofulvin as standard antimicrobial drugs. Most of the tested compounds depicted excellent antimicrobial activities on comparison with standard drugs.



Foroumadi et al synthesized a series of N-[5-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole-2-yl] and N-[5-(nitrophenyl)-1,3,4-thiadiazole-2-yl]piperazinylquinolone derivatives and evaluated for *in vitro* antibacterial activity against some gram-positive and Gram-negative bacteria. The antibacterial data revealed that all nitroimidazole derivatives showed interesting activity against tested gram-positive bacteria (MIC=0.008-0.03 µg/ml) while they did not show good activity against gram-negative organisms. All nitrophenyl analogues were inactive. Among all of the tested compounds (Ciprofloxacin derivative in nitroimidazole series) exhibited excellent activity against *Staphylococcus aureus* and *Staphylococcus epidermidis* (MIC=0.008 µg/ml).




Karabasanagouda et al. synthesized some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles which were screened for their antibacterial activity against *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* bacterial strains and for antifungal activity against *Aspergillus flavus*, *Aspergillus fumigatus*, *Penicillium marneffei* and *Trichophyton mentagrophytes*. One compound with methyl substitution was found to be the most potent compound of the series by having MIC value of 6.25 µg/ml on comparison with Ciprofloxacin and cyclopiroxolamine as standard drug. The good activity is attributed to the presence of pharmacologically active -CH₃, OCH₃, NH₂, and 2,3-dichloro groups attached to phenyl group at position 6 of the thiadiazole ring. Results of antifungal screening showed that the presence of S-CH₃ and S-C₂H₅ groups at position 4 of phenoxy group caused increased activity.




R- 2-Cl; 4-CH₃; 4-OCH₃; 2,3-(Cl)₂; 4-NH₂


Pintilie et al synthesized some novel N-(5-(3-(methylthio)propyl)-1,3,4-thiadiazol-2-yl)benzamide derivatives and investigated for their antimicrobial activities against five standard bacterial strains *Staphylococcus aureus*, *Bacillus anthracis*, *Bacillus cereus*, *Sarcinalutea* and *Escherichia coli* by using double dilution method. Some of the investigated compounds exhibited excellent antimicrobial activities on comparison with their respective standard drugs. The most active compound against *B. anthracis* and *B. cereus* was a compound with a 4-methylphenyl moiety on the heterocyclic ring.



Dubey et al synthesized 1,3,4 thiadiazole-1,3,5-triazine derivatives and evaluated their antimicrobial activity against bacterial strains like *Pseudomonas aeruginosa*, *Bacillus cereus*, *Escherichia coli* and *Bacillus subtilis*. Compounds with chloro-substitution on phenyl amine position connected to 1,3,5-triazine core exhibit significant activity against *Pseudomonas aeruginosa* (6.25 µg /mL), moderate activity against *Bacillus cereus* and *Escherichia coli* (12.5 µg/mL).




Seelametal synthesized a novel series of 1, 3, 4-thiadiazoles which are incorporated with isoxazolo-thiazole moieties and screened for their antimicrobial activity. The screened compounds with chlorine substituted showed high antibacterial activity against all the strains against *B. subtilis* and *B. thuringiensis* with MIC 3.125 µg/ml as compared with standard drug Streptomycin. Compound having 4-OCH₃ showed equipotent activity to flucan against all the strains *C. albicans*, *fabae*, *F. oxysporum* (MIC, 3.125 µg/ml).



R- 4-Cl; 2-Cl; 4-N(Me)₂; 3-NO₂; 4-OCH₃; 4-CH₃


Atta et al synthesized novel imidazo[2,1-b]-1,3,4-thiadiazoles and evaluated for their antimicrobial activity against *Staphylococcus aureus*, *Candida albicans*, *Pseudomonas aeruginosa* and *Escherichia coli* using agar diffusion method Ampicillin and Clotrimazole were used as reference drugs.



X- H; Br; Cl; I

Y- H; Br; Cl


Noolvi et al synthesized 2-(4-formyl-2- methoxyphenoxy) acetic acid and screened for their antimicrobial activity against *S. aureus*, *S. enterica*, *V. cholera*, and antifungal activity against *C. albicans*.




R- H; 2-OCH₃; 3-NO₂; 4-NO₂; 4-Cl; 4-NH₂; 2,4-diOH;4-OH; 3-C

Bhardwaj et al synthesized new pyridine imidazo[2,1b]-1,3,4-thiadiazole derivatives and screened for their antimicrobial activity using cup-plate agar diffusion method against bacteria *B. pumillus*, *S. aureus*, *V. cholera*, *E. coli*, *P. mirabilis*, and *P. aeruginosa* and fungal culture of *C. albicans*. Some compound showed excellent inhibition of *B. pumillus*(95.1%), *P. aeruginosa*(94.6%), *V. cholera* (91.0%), *S. aureus*(88.8%), and one compound demonstrated inhibition of *P. mirabilis* (87.8%) when compared with standard drug Ampicillin and Amphotericin


Al-Qawasmeh et al., synthesized 9-cyclopropyl-4-fluoro-6-oxo-6,9-dihydro-[1,2,5]thia-diazolo[3,4-h]quinoline-7-carboxylic acid and ethyl ester derivatives and tested for their antimicrobial activities *in vitro* against a wide spectrum of Gram-positive and Gram-negative bacteria, yeasts and moulds taking Ciprofloxacin as reference drug. Most of the compounds were active but one compound showed excellent activity against Gram-positive bacilli and staphylococci (MICs = 0.015-1.5 μg/mL), including methicillin-resistant *Staphylococcus aureus*, and against most of the Gram-negative bacteria tested (MICs = 0.07-3 μg/mL).



Gopalakrishnan et al synthesized 5,7-diaryl-4,4-dimethyl-4,5,6,7-tetrahydropyridine [3,4-d]-1,2,3thiadiazoles. All of the newly synthesized novel target molecules were tested for their antibacterial activity *in vitro* against *Staphylococcus aureus*, β-Haemolytic streptococcus, *Vibrio cholerae*, *Salmonella typhi*, *Shigella flexneri*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas* by using Ciprofloxacin as standard drug for comparison. Synthesized compounds exerted a wide range of modest antibacterial activity and modest *in vitro* antifungal activity against *Rhizopus* and *M. Gypseum*, compared to the standard drug Fluconazole.




Liesen et al synthesized N-(4-methoxyphenyl)-5-(5-methyl-1H-imidazol-4-yl)-1,3,4-thiadiazole-2-amine derivatives. One compound was found to be the most potent compound with MIC value 130 μg/ml as compared with standard drug Chloramphenicol and Rifampicin for antibacterial activity.



Murthy et al supported the synthesis of some new (3,5-dichloro-4-((5-aryl-1,3,4-thiadiazol-2-yl)methoxy)phenyl)aryl methanones and investigated for their antimicrobial activities by agar well diffusion method. Gentamicin (antibacterial drug) and Nystatin (antifungal drug) were used for comparison. The compound with methyl substitution was found to exhibit significant antibacterial activity at lower concentration, against Gram positive bacteria such as *Bacillus subtilis*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Bacillus cereus* and Gram negative bacteria

such as *E. coli*, *Pseudomonas aeruginosa*, *Salmonella typhi*, and *Klebsiella pneumoniae*. Results indicate that the compound with electron-donating groups exhibited broad spectrum antimicrobial activity against both bacteria and fungi.



COVID-19: Drug targets and potential treatments

All CoVs enzymes and proteins involved in viral replication are potential drug targets in the search for therapeutic options for SARS-CoV-2. This review provides an overview of the main targets from a structural point of view, together with reported therapeutic compounds with activity against SARS-CoV-2 and/or other CoVs. Also, the role of immune response to coronavirus infection and the related therapeutic options are presented (reference provided).

This novel CoV belongs to the Coronaviridae family as well as SARS CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV). Highly pathogenic CoVs are enveloped, positive polarity single-stranded RNA betacoronavirus and their genomes encode non-structural proteins (nsps), structural proteins and several accessory proteins.

The SARS-CoV-2 infection process starts with the viral entry mediated by the interaction of the spike (S) glycoprotein with the host angiotensin-converting enzyme 2 (ACE2) receptor, and the S protein cleavage by the host transmembrane serine protease 2 (TMPRSS2) prior to the fusion to the host cell membrane. SARS-CoV-2 infection is profoundly inhibited with lysosomotropic drugs (99% and 98% respectively) in cells transduced with pseudovirus.






Fig 1: SARS-Cov-2 Infection Cycle

Systemic peptide mapping on SARS-CoV allowed to discover the peptide CP-1, which binds with high affinity the heptad-repeat 2 region of S2 and interferes with the conformational changes leading to the 6-helix bundle formation and thus blocking Virus cell fusion process. Recently, a pan-coronavirus fusion inhibitor lipopeptide (EK1C4) has been designed, targeting a structure formed by two specific regions in the S2 subunit.



Compounds and Peptides directed to S- Protein

GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE




RdRp inhibitors active against SARS-CoV-2 and under clinical trials

Host-based druggable Targets :


In SARS-CoV-2, the angiotensin I converting enzyme 2 (ACE2) has been recently confirmed as the main virus receptor. Therefore, inhibition or modulation of ACE2 represents one of the proposed host-based strategies for treatment of SARS CoV-2. ACE2 can be found in epithelial cells of lung, liver and testis. ACE2 was already known for mediating infection of the less pathogenic SARS-CoV, in particular, by recognizing the receptor-binding domain of the S protein (S1 RBD) with an helical region located in the peptidase domain.

The host cell surface transmembrane serine protease 2 (TMPRSS2) activates S protein present in the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV.1.




TMPRSS2 modulators. A) Chemical structure of TMPRSS2 inhibitors. B) Some transcriptional inhibitors of TMPRSS2

The adaptor-associated kinase 1 (AAK1) and cyclin G-associated kinase (GAK) are host Y8 protein kinases that regulate intracellular viral trafficking during entry, assembly and release of multiple unrelated RNA viruses such as rabies, Ebola, dengue or hepatitis C virus. In the recent past, repurposing marketed drugs or optimizing valuable hits such as 3,5-disubstituted-pyrrolo[2,3-b]pyridines as potent AAK1 and GAK inhibitors could be a good strategy to avoid SARS-CoV-2 entry.



AAK1 and GAK inhibitors with therapeutic potential for COVID-19


The two-pore channels (TPC1-3) regulate the conductance of sodium and calcium ions across cellular membranes. These are involved in the regulation of endolysosomal trafficking and Ebola entry in the host cell.




Clinical used drugs blockers of TPC2. A) Dopamine antagonists, B) SERMs

Therapeutic targeting of the innate immune response:

It has been known that a cytokine storm results from an overreaction of the immune system in SARS and MERS patients. Clinical findings showed exuberant inflammatory responses during SARS-CoV-2 infection, further resulting in uncontrolled pulmonary inflammation, likely leading case fatality. The repurposing of host-based therapeutics to control immune response may counterattack COVID-19. Some of these treatments include the use of recombinant IFN- α and IFN- γ as antiviralcytokines that inhibit viral replication in targeted cells. Some studies have reported that IFN- α alone has more effect against SARS-CoV-2 than IFN- α *in vitro*. In fact, combinations of IFN- α and IFN- γ with other antivirals such as ribavirin and/or lopinavir/ritonavir (HIV treatment) have a synergistic effect *in vitro* and in animal models. *In vitro* and *in vivo* studies show the protective effect of Type III IFN 2L₃ treatment against SARS-CoV infection, that possibly in combination with IFN-I- could be an effective treatment for SARS-CoV-2. It has been shown recently that the potential benefits from low-dose corticosteroids treatment in SARS-CoV-2 critically ill patients. Another immunosuppressor, tocilizumab, an humanized monoclonal antibody against the interleukin IL-6 receptor reduces proinflammatory response in COVID-19 patients. Immunosuppressor treatments successfully used against other viruses, could be also used for COVID-19. These would include JAK inhibitors such as tofacitinib, baricitinib, and the recently approved upadacitinib, previously used in rheumatoid arthritis blinatumomab and HDAC inhibitors such as vorinostat or belinostat. Baricitinib is also a potent inhibitor of AAK1 and may also influence in decreasing viral infectivity, being a good candidate for clinical trials of COVID-19.




Immunosuppression potential treatments. A) antiviral used in combination with IFN- α and IFN- β B) JAK inhibitors, C) HDAC inhibitors.






Anti-IFV-A agents with potential therapeutic effects on SARS-CoV-2.

Therapeutic options in clinical trials for COVID-19:

Antivirals lopinavir/ritonavir have been recommended for clinical treatment for COVID-19. However, recent results from clinical trials do not confirm any benefit in hospitalized adult patients with severe COVID-19, but the combination of these two antivirals with interferon is found to be more promising for patients. Remdesivir is an adenosine analogue RdRp inhibitor with antiviral protection against SARS-CoV-2 and other viruses. Intravenous administration has been found to be efficacious in an American patient with COVID 19. Based on these results, Gilead Company provided the compound to China to perform the first clinical trials in SARS-CoV-2-infected individuals (Clinical trials NCT04257654/6). The FDA has approved the emergency use of this drug for COVID-19 patients with severe symptoms. Arbidol (umifenovir) is able to block viral fusion against influenza viruses. The antiviral activity of umifenovir against SARS-CoV-2 has been confirmed *in vitro*. First clinical data from patients with laboratory-confirmed COVID-19 points to a superior efficacy of umifenovir monotherapy to lopinavir/ritonavir treatment. Also, other drugs used for influenza as Avigan (favipiravir) and Tamiflu (oseltamivir) have been used in patients.



Antivirals used in clinic as potential COVID-19 treatment



Some of the approved drugs in clinical trials for COVID-19. A) Inhibitors of viral RNA polymerase, B) antipsychotics effective in clathrin-mediated endocytosis, C) miscellaneous drugs

Conclusions

In this report, we have described a brief review on the recent progress in the synthesis and biological activity studies of various Thiadiazole derivatives, an important class of heterocyclic compounds suitable as drug candidates for various drug targets.

Also focused in the present report, the structural druggable sites and determinants of antibodies efficacy against S Protein. The significance of structural spike(S) protein is remarkable due to its main role in the SARS-CoV-2 entry through the host receptor ACE2. Targetting human proteins is an excellent alternative and another promising way is the combination of available antiviral drugs acting through different targets in a multi-target strategy that has proven to increase efficacy during the recent current pandemic. It has been found during the recent pandemic that the repurposing of approved drugs is the only possibility to find a timely effective treatment. However, the coronavirus outbreaks require thorough preparedness not only for the current situation but also for a future potential reemergence of novel coronaviruses. Hence it is of utmost importance to design drugs acting as pan-coronavirus antivirals or through a multi-target approach to avoid lack of effectiveness by viral mutation escape.

Acknowledgements

The authors thank the GITAM management for the encouragement and the DST, Govt of India for the DST-FIST program for the department of Chemistry, School of Science, GITAM Deemed to be University, Visakhapatnam. The references are cited appropriately wherever required in this review article and gratefully acknowledge the authors of the references.

References

1. Abdou O Abdelhamid¹, Ibrahim E El Sayed², Mohamed Z Hussein³, Mangoud M Mangoud, Aug 2016, Synthesis and Antimicrobial Activity of Some New Thiadiazoles, Thioamides, 5-Arylazothiazoles and Pyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidines. *Molecules (Basel, Switzerland)*, 17 21(8)DOI: 10.3390/molecules 21081072
2. Mohamed M.Azaam^aEl-RefaieKenawy^aAhmed S. BadrEl-din^{ab}AbeerA.Khamis^cMohammedA.El-Magd^dJune 2017Antioxidant and Anticancer Activities of α -Aminophosphonates Containing Thiadiazole Moiety, *Journal of Saudi Chemical Society*22(1) (2017),. doi:10.1016/j.jscs.2017.06.002.
3. MalleshappaN.Noolvi^aHarunM.Patel^bSaritaKamboj^cSwaranjitSinghCameotra^d2012, Synthesis and antimicrobial evaluation of novel 1,3,4-thiadiazole derivatives of 2-(4-formyl-2-methoxyphenoxy) acetic acid. *Arabian Journal of Chemistry*doi:10.1016/j.arabjc.2012.02.
4. Eman M Flefel^{1,2}, Wael A El-Sayed³, Ashraf M Mohamed^{4,5}, Walaa I El-Sofany⁶, Hanem M Awad⁷2017,Synthesis and Anticancer Activity of New 1-Thia-4-azaspiro[4.5]decane, their Derived

Thiazolopyrimidine and 1,3,4-Thiadiazole Thioglycosides *Molecules*, 22(1), 170; doi.10.3390/molecules22010170.

5. Ameen Ali Abu-Hashem^{1,2}, Sami A Al-Hussain³ 2022 Jan 27 Synthesis of New 1,2,4-Triazole/1,3,4-Thiadiazole with Spiroindoline, Imidazo[4,5-b]quinoxaline and Thieno[2,3-d]pyrimidine from Isatin Derivatives as Anticancer Agents, *molecules*. doi: 10.3390/molecules27030835

6. Ramakrishna Teja^b, Sivakrishna Kapu^b, Swapana Kadiyala^b, Visagaperumal Dhanapal^b, Anbalagan Navaneetha Raman^a 2012, Heterocyclic systems containing bridgehead nitrogen atom: Synthesis and antimicrobial activity of thiadiazolo[2',3':2,3]imidazo[4,5-B]quinoxaline, *Journal of Saudi Chemical Society*, Feb; 27(3): 835, doi.org/10.1016/j.jscs.2012.12.01

7. Nisha Aggarwal¹, Rajesh Kumar, Prem Dureja, Jitender Mohan Khurana 28 December 2011 Synthesis of Novel Nalidixic Acid-Based 1,3,4-Thiadiazole and 1,3,4-Oxadiazole Derivatives as Potent Antibacterial Agents, *Chemical Biology & Drug Design*, 79(4):384-97 DOI:10.1111/j.1747-0285.2011.01316.x

8. Nida N. Farshori^a, Mudasir R. Banday^a, Anis Ahmad^b, Asad U. Khan^b, Abdul Rauf^a 1 February 2010 Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles, *Bioorganic and medicinal chemistry* 2010 Mar 15; 20(6):1933-8. doi: 10.1016/j.bmcl.2010.01.126. 1.

9. Vaibhav Dubey¹, Manish Pathak, Hans R Bhat, Udaya P Singh Dec. 2012 Design, Facile Synthesis, and Antibacterial Activity of Hybrid 1,3,4-thiadiazole-1,3,5-triazine Derivatives Tethered via -S- Bridge, *Chem Biol Drug* ; 80: 598–604

10. Naresh Varma Seelam^{1*}, Satya P. Shrivastava² and Somarouthu Prasanthi 1 June 16, 2013 Synthesis and antimicrobial activity of some novel fused heterocyclic moieties, *Org. Commun.* (2013) 6:2 78-85.

11. Raed A. Al-Qawasmeh, a Jalal A. Zahra, a Franca Zani, b Paola Vicini, b, * Roland Boese, c and Mustafa M. El-Abadelaha, * September 2009, Synthesis and antibacterial activity of 9-cyclopropyl-4-fluoro-6-oxo-6,9-dihydro-[1,2,5] thiadiazolo [3,4-h] quinoline-7-carboxylic acid and its ethyl ester. *Archive for organic chemistry*, (12):322 DOI:10.3998/ark.5550190.0010.c2.

12. M. Gopalakrishnan, J. Thanusu, V. Kanagarajan & R. Govindaraju . Oct 16, 2008 Synthesis, antibacterial, and antifungal activities of biolabile (E)-1-(4-morpholinophenyl)-3-aryl-prop-2-en-1-ones. *Medicinal Chemistry Research*, Volume 18 (5) .

13. Sandrine Belouzard¹, Jean K Millet, Beth N Licitra, Gary R Whittaker 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. *Viruses* 2012 Jun; 4(6):1011-33.

14. Rolf Hilgenfeld¹. 2014. From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design. *FEBS J.*; 281:4085–96. - PMC – PubMed

15. Haitao Yang¹, Mark Bartlam, Zihe Rao. 2006 Drug design targeting the main protease, the Achilles' heel of coronaviruses. *Curr Pharm Des.*; 12:4573–90. - PubMed

16. Chung-ke Chang¹, Shou-Chen Lo², Yong-Sheng Wang², Ming-Hon Hou³ 2016. Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. *Drug Discov Today*. 2016;21:562–72. - PMC - PubMed
17. Catharine I Paules¹, Hilary D Marston², Anthony S Fauci² 2020. Coronavirus infections-More than just the common cold. *JAMA*. 2020;323:707. - PubMed
18. Aisha M Al-Osail¹, Marwan J Al-Wazzah¹ 2017. The history and epidemiology of Middle East respiratory syndrome corona virus. *Multidiscip Respir Med.*;12:20. - PMC - PubMed
19. Entedar A J Alsaadi^{1,2,12}, Ian M Jones¹. 2019. Membrane binding proteins of coronaviruses. *Future Virology.*;14:275–86.
20. Ruth McBride¹, Marjorie van Zyl², Burtram C Fielding³ 2014. The coronavirus nucleocapsid is a multifunctional protein. *Viruses*. 2014;6:2991–3018. - PMC - PubMed
21. Yong Guo¹, Christine Korteweg, Michael A McNutt, Jiang Gu, 2008;. Pathogenetic mechanisms of severe acute respiratory syndrome. *Virus Res*. 2008;133:4–12. - PMC - PubMed
22. Jiang Gu¹, Christine Korteweg. 2007; Pathology and pathogenesis of severe acute respiratory syndrome. *Am J Pathol*. 2007;170:1136–47. - PMC - PubMed
23. Yanqing Ding¹, Li He, Qingling Zhang, Zhongxi Huang, Xiaoyan Che, Jinlin Hou, Huijun Wang, Hong Shen, Liwen Qiu, Zhuguo Li, Jian Geng, Junjie Cai, Huixia Han, Xin Li, Wei Kang, Desheng Weng, Ping Liang, Shibo Jiang. . 2004. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications for pathogenesis and virus transmission pathways. *J Pathol*. 2004;203:622–30. - PMC - PubMed
24. Wenhui Li¹, Michael J Moore, Natalya Vasilieva, Jianhua Sui, Swee Kee Wong, Michael A Berne, Mohan Somasundaran, John L Sullivan, Katherine Luzuriaga, Thomas C Greenough, Hyeryun Choe, Michael Farzan. 2003 .Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature*. 2003;426:450–4. - PMC - PubMed
25. Ayman Mubarak¹, Wael Alturaiki², Maged Gomaa Hemida^{3,4}. 2019 Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development. *J Immunol Res*. 2019;2019:1–11. - PMC - PubMed
26. Aartjan J W te Velthuis¹, Sjoerd H E van den Worm, Eric J Snijder. 2012. The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension. *Nucleic Acids Res*. 2012;40:1737–47. - PMC - PubMed
27. Christopher C Stobart¹, Nicole R Sexton, Havisha Munjal, Xiaotao Lu, Katrina L Molland, Sakshi Tomar, Andrew D Mesecar, Mark R Denison. 2013. Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity. *J Virol*. 2013;87:12611–8. - PMC - PubMed
28. Haofeng Wang¹, Song Xue¹, Haitao Yang², Cheng Chen³. 2016. Recent progress in the discovery of inhibitors targeting coronavirus proteases. *Virol Sin*. 2016;31:24–30. - PMC - PubMed

29. Tingting Hu¹, Cheng Chen², Huiyan Li¹, Yanshu Dou¹, Ming Zhou¹, Deren Lu¹, Qi Zong¹, Yulei Li³, Cheng Yang⁴, Zhihui Zhong⁵, Namit Singh⁶, Honggang Hu³, Rundong Zhang^{1,7}, Haitao Yang², Dan Su¹. 2017 .Structural basis for dimerization and RNA binding of avian infectious bronchitis virus nsp9. *Protein Sci.* 2017;26:1037–48. - PMC - PubMed
30. Mickaël Bouvet¹, Adrien Lugari², Clara C Posthuma³, Jessika C Zevenhoven³, Stéphanie Bernard², Stéphane Betzi², Isabelle Imbert¹, Bruno Canard¹, Jean-Claude Guillemot¹, Patrick Lécine⁴, Susanne Pfefferle⁵, Christian Drosten⁵, Eric J Snijder³, Etienne Decroly⁶, Xavier Morelli⁷ 2014 .Bouvet Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes. *J Biol Chem.* 2014;289:25783–96. - PMC - PubMed
31. K Narayanan¹, A Maeda, J Maeda, S Makino. 2000 .Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. *J Virol.* 2000;74:8127–34. - PMC - PubMed
32. Emmie de Wit¹, Neeltje van Doremalen¹, Darryl Falzarano², Vincent J Munster¹. . 2016 .SARS and MERS: Recent insights into emerging coronaviruses. *Nat Rev Microbiol.* 2016;14:523–34. - PMC - PubMed
33. Jose L Nieto-Torres¹, Marta L Dediego, Enrique Alvarez, Jose M Jiménez-Guardeño, Jose A Regla-Nava, Mercedes Llorente, Leonor Kremer, Shen Shuo, Luis Enjuanes. 2011. Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein. *Virology.* 2011;415:69–82. - PMC - PubMed
34. Lanying Du¹, Yuxian He, Yusen Zhou, Shuwen Liu, Bo-Jian Zheng, Shibo Jiang. 2009 .The spike protein of SARS-CoV--a target for vaccine and therapeutic development. *Nat Rev Microbiol.* 2009;7:226–36. - PMC - PubMed
35. Shing-Yen Lin¹, Chia-Ling Liu, Yu-Ming Chang, Jincun Zhao, Stanley Perlman, Ming-Hon Hou. 2014. Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target. *J Med Chem.* 2014;57:2247–57. - PMC - PubMed
36. Yasuhiro Shimamoto¹, Yasunao Hattori¹, Kazuya Kobayashi¹, Kenta Teruya², Akira Sanjoh³, Atsushi Nakagawa⁴, Eiki Yamashita⁴, Kenichi Akaji⁵. 2015. Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CLprotease inhibitors. *Bioorg Med Chem.* 2015;23:876–90. - PMC - PubMed
37. Andrew D Meseca, Yahira M Báez-Santos¹, Scott J Barraza, Michael W Wilson, Michael P Agius, Anna M Mielech, Nicole M Davis, Susan C Baker, Scott D Larsen. 2014. X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. *J Med Chem.* 2014;57:2393–412. - PMC - PubMed
38. Arun K Ghosh¹, Jun Takayama, Kalapala Venkateswara Rao, Kiira Ratia, Rima Chaudhuri, Debbie C Mulhearn, Hyun Lee, Daniel B Nichols, Surendranath Baliji, Susan C Baker, Michael E Johnson, Andrew D Mesecar. 2010. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: Design, synthesis, protein-ligand X-ray structure and biological evaluation. *J Med Chem.* 2010;53:4968–79. - PMC - PubMed

Holmes.2004.CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. *Proc Natl Acad Sci U S A*. 2004;101:15748–53. - PMC - PubMed

50. Madhavi, B. and Veera Raghava Sharma, G., Studies on Thiadiazole heterocyclic compounds (Unpublished results)